A vaccine available, an answer still missing

On August 21, UN coordinator Julien Harneis describes an outbreak growing faster than the response: roughly 2,500 deaths, half in the previous twenty days. He later clarifies that the toll has already passed that threshold. An additional tool matters all the more, but must not obscure this acceleration.^[4]

What can an exposed health worker honestly be promised? Not yet proven protection against Bundibugyo. On August 20, WHO and Africa CDC announced 70,000 Ervebo doses for Congo: 20,000 for a trial and 50,000 for frontline workers. The vaccine is licensed against a different Ebola species. Uncertain efficacy in this outbreak is the reason for testing it, not a detail to omit when seeking consent.^[1]

The response is also progressing. Harneis describes five operational packages combining surveillance, care and community work, with the government paying more health workers. This qualifies our private August 14 preparation, centred on unpaid staff and Nizi's partial walkout. Restoration of care there is not established. The briefing also says doses have been provided, then that deployment is being arranged: those formulations cannot certify arrival with each team. At August 21, our original test of sustained patient intake at Nizi and actual payment of its teams therefore remains unresolved. Harneis also warns that the response’s startup funding will run out within weeks.^[2][4]

Acting without certainty can be responsible when people understand what is known, what is not and what they may refuse. Our standard is that refusal must not cost them other care; the announcement cannot establish that guarantee in practice. The new September 4 review concerns the protocol and participant information; it is additional to the Nizi follow-up. This is progress worth taking seriously, on one condition: exposed people are not merely the place where science collects its answer.^[1]